❶ statistically confirm previous pilot (Phase I) clinical data showing that the combination of high-definition white light endoscopy (HD-WLE) and FME using labelled bevacizumab improves early EC detection over the current clinical standard (i.e. HD-WLE and random biopsy) and

❷ validate EC biomarkers recently identified by genetic screening as targets for further improving EC detection and disease stratification over using labelled bevacizumab, based on retrospective analysis of BE patient specimen. Earlier detection and better stratification can lead to more effective therapy and thus save lives and healthcare costs. Therefore, successful implementation of ESCEND could lead to an enormous socio-economic impact.